KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Current Deferred Revenue (2016 - 2025)

Charles River Laboratories International has reported Current Deferred Revenue over the past 17 years, most recently at $210.4 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $210.4 million for Q4 2025, down 15.26% from a year ago — trailing twelve months through Dec 2025 was $210.4 million (down 15.26% YoY), and the annual figure for FY2025 was $210.4 million, down 15.26%.
  • Current Deferred Revenue for Q4 2025 was $210.4 million at Charles River Laboratories International, down from $237.7 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for CRL hit a ceiling of $290.0 million in Q4 2022 and a floor of $210.4 million in Q4 2025.
  • Median Current Deferred Revenue over the past 5 years was $249.4 million (2024), compared with a mean of $245.6 million.
  • Biggest five-year swings in Current Deferred Revenue: surged 35.75% in 2021 and later decreased 15.26% in 2025.
  • Charles River Laboratories International's Current Deferred Revenue stood at $219.7 million in 2021, then soared by 32.0% to $290.0 million in 2022, then dropped by 5.86% to $273.0 million in 2023, then dropped by 9.04% to $248.3 million in 2024, then decreased by 15.26% to $210.4 million in 2025.
  • The last three reported values for Current Deferred Revenue were $210.4 million (Q4 2025), $237.7 million (Q3 2025), and $268.3 million (Q2 2025) per Business Quant data.